Skip to main content
Premium Trial:

Request an Annual Quote

Eleanor Dodson, Venki Ramakrishnan, Prabhavathi Fernandes, Sven Rohmann, Erich Mayer, Carl Weissman, Leroy Hood, Michael Steinmetz, Bob Nelsen

Premium

Protein crystallographers Eleanor Dodson and Venki Ramakrishnan were elected as fellows of the Royal Society last month. Dodson is a professor and research fellow at the University of York, UK; Ramakrishnan is a professor and senior scientist at the MRC Laboratory of Molecular Biology in Cambridge, UK.

 

Prabhavathi Fernandes has joined the supervisory board of Martinsried, Germany-based GPC Biotech. Most recently, she was CEO of Ricerca Biosciences. Prior to that, she was a co-founder and CEO of Small Molecule Therapeutics, a company that merged with Morphochem in 2000. Before that, she held positions at Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories, and The Squibb Institute for Medical Research. She received a PhD in microbiology from Thomas Jefferson University in Philadelphia.

 

Sven Rohmann has become CEO of Hanover, Germany-based BioVision. He is also a managing partner of Nextech Venture. In the past, Rohmann held a management position at Merck. He is also a co-founder and former CEO of Ganymed Pharmaceuticals. BioVision also appointed two new members to its supervisory board: Erich Mayer, a managing partner of IMH Industrie Mangement Holding; and Alfred Scheidegger, a managing partner at Nextech Venture.

 

Carl Weissman has become president and CEO of newly-formed Accelerator, a collaboration between MPM Capital, Arch Venture Partners, Versant Venture, Alexandria Real Estate Equities, and the Institute of Systems Biology that aims to help startup companies affiliated with the ISB get off the ground. Members of Accelerator’s board of directors include: Leroy Hood, president and director of ISB; Michael Steinmetz, general partner of MPM Capital; and Bob Nelsen, managing director of Arch Venture Partners.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.